Oliver Gross

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6410647/publications.pdf

Version: 2024-02-01

78 papers	7,550 citations	76326 40 h-index	58581 82 g-index
89 all docs	89 docs citations	89 times ranked	9305 citing authors

#	Article	IF	Citations
1	Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study. Nephrology Dialysis Transplantation, 2022, 37, 2496-2504.	0.7	16
2	Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models. Cells, 2022, 11, 594.	4.1	17
3	Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adultsâ€“an update for 2020. Pediatric Nephrology, 2021, 36, 711-719.	1.7	70
4	Precise variant interpretation, phenotype ascertainment, and genotypeâ€“phenotype correlation of children in the <scp>EARLY PROâ€TECT</scp> Alport trial. Clinical Genetics, 2021, 99, 143-156.	2.0	7
5	Response to: Diagnosis of Alport syndrome, is there a role for skin biopsy?. Pediatric Nephrology, 2021, 36, 1031-1031.	1.7	0
6	Mutations in PRDM15 Are a Novel Cause of Galloway-Mowat Syndrome. Journal of the American Society of Nephrology: JASN, 2021, 32, 580-596.	6.1	15
7	Genotypeâ€“phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatric Nephrology, 2021, 36, 2719-2730.	1.7	19
8	Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome. Journal of Clinical Medicine, 2021, 10, 2958.	2.4	7
9	Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Hereditary Podocytopathies, Alport Syndrome, and FSGS: A Case Series to Better Plan a Large-Scale Study. Cells, 2021, 10, 1815.	4.1	19
10	Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study. Journal of Clinical Medicine, 2021, 10, 3049.	2.4	12
11	Addressing the â€˜hypoxia paradoxâ€™ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. Molecular Medicine, 2021, 27, 120.	4.4	9
12	Collagen IVÎ±345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpastureâ€™s and Alport diseases. Journal of Biological Chemistry, 2021, 296, 100590.	3.4	19
13	The importance of clinician, patient and researcher collaborations in Alport syndrome. Pediatric Nephrology, 2020, 35, 733-742.	1.7	15
14	SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet, The, 2020, 396, 597-598.	13.7	253
15	Characterization of Sensorineural Hearing Loss in Children with Alport Syndrome. Life, 2020, 10, 360.	2.4	7
16	Multiorgan and Renal Tropism of SARS-CoV-2. New England Journal of Medicine, 2020, 383, 590-592.	27.0	1,523
17	COVID-19-associated nephritis: early warning for disease severity and complications?. Lancet, The, 2020, 395, e87-e88.	13.7	84
18	A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alportâ€™s syndrome. Kidney International, 2020, 97, 1275-1286.	5.2	94

#	Article	IF	Citations
19	Clinical trial recommendations for potential Alport syndrome therapies. Kidney International, 2020, 97, 1109-1116.	5.2	7
20	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
21	Genetische Ursachen und Therapie beim Alport-Syndrom. Medizinische Genetik, 2019, 30, 429-437.	0.2	0
22	Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatric Nephrology, 2019, 34, 1175-1189.	1.7	97
23	The Hypomorphic Variant p.(Gly624Asp) in COL4A5 as a Possible Cause for an Unexpected Severe Phenotype in a Family With X-Linked Alport Syndrome. Frontiers in Pediatrics, 2019, 7, 485.	1.9	11
24	Kidney Injury by Variants in the COL4A5 Gene Aggravated by Polymorphisms in Slit Diaphragm Genes Causes Focal Segmental Glomerulosclerosis. International Journal of Molecular Sciences, 2019, 20, 519.	4.1	13
25	Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. Kidney International, 2019, 95, 1103-1119.	5.2	14
26	Alport syndrome: a unified classification of genetic disorders of collagen IV Î±345: a position paper of the Alport Syndrome Classification Working Group. Kidney International, 2018, 93, 1045-1051.	5.2	206
27	Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 317-325.	6.1	64
28	Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrology Dialysis Transplantation, 2017, 32, gfw095.	0.7	40
29	Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKDâ€“Related Systemic Inflammation. Journal of the American Society of Nephrology: JASN, 2017, 28, 76-83.	6.1	196
30	Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations. Pediatric Nephrology, 2017, 32, 131-137.	1.7	29
31	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. Nephrology Dialysis Transplantation, 2016, 31, 1002-1013.	0.7	46
32	Preclinical Alterations in the Serum of COL(IV)A3^{â€“}/^{â€“} Mice as Early Biomarkers of Alport Syndrome. Journal of Proteome Research, 2015, 14, 5202-5214.	3.7	11
33	Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. New England Journal of Medicine, 2015, 373, 2225-2236.	27.0	516
34	Effects of mycophenolate mofetil on kidney function and phosphorylation status of renal proteins in Alport COL4A3-deficient mice. Proteome Science, 2014, 12, 56.	1.7	6
35	Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. Nephrology Dialysis Transplantation, 2014, 29, 1012-1019.	0.7	27
36	Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrology Dialysis Transplantation, 2014, 29, iv124-iv130.	0.7	38

#	Article	IF	Citations
37	Challenges for Academic Investigatorâ€“Initiated Pediatric Trials for Rare Diseases. Clinical Therapeutics, 2014, 36, 184-190.	2.5	7
38	Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice. Matrix Biology, 2014, 34, 13-21.	3.6	60
39	Diagnosis of Alport syndromeâ€”search for proteomic biomarkers in body fluids. Pediatric Nephrology, 2013, 28, 2117-2123.	1.7	16
40	Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric Nephrology, 2013, 28, 5-11.	1.7	118
41	Expert Guidelines for the Management of Alport Syndrome and Thin Basement Membrane Nephropathy. Journal of the American Society of Nephrology: JASN, 2013, 24, 364-375.	6.1	285
42	Alport syndromeâ€”insights from basic and clinical research. Nature Reviews Nephrology, 2013, 9, 170-178.	9.6	202
43	Discoidin Domain Receptor 1 Protein Is a Novel Modulator of Megakaryocyte-Collagen Interactions. Journal of Biological Chemistry, 2013, 288, 16738-16746.	3.4	42
44	Outcomes of Male Patients with Alport Syndrome Undergoing Renal Replacement Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1969-1976.	4.5	56
45	Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney International, 2012, 81, 779-783.	5.2	113
46	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney International, 2012, 81, 494-501.	5.2	275
47	Tumour necrosis factorâ€Î± drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. Journal of Pathology, 2012, 226, 120-131.	4.5	51
48	Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in nonâ€inflammatory glomerular injury. Journal of Pathology, 2012, 228, 482-494.	4.5	59
49	Renal Protective Effects of Aliskiren Beyond Its Antihypertensive Property in a Mouse Model of Progressive Fibrosis. American Journal of Hypertension, 2011, 24, 355-361.	2.0	47
50	Differential Kidney Proteome Profiling in a Murine Model of Renal Fibrosis under Treatment with Mycophenolate Mofetil. Pathobiology, 2011, 78, 162-170.	3.8	12
51	Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-Î±-mediated podocyte loss. Kidney International, 2011, 79, 189-198.	5.2	50
52	Mycophenolic Acid Displays IMPDH-Dependent and IMPDH-Independent Effects on Renal Fibroblast Proliferation and Function. Therapeutic Drug Monitoring, 2010, 32, 405-412.	2.0	19
53	Drug-Induced Granulomatous Interstitial Nephritis in a Patient With Ankylosing Spondylitis During Therapy With Adalimumab. American Journal of Kidney Diseases, 2010, 56, e17-e21.	1.9	42
54	Integrin Î±2-deficient mice provide insights into specific functions of collagen receptors in the kidney. Fibrogenesis and Tissue Repair, 2010, 3, 19.	3.4	53

#	Article	IF	Citations
55	Interstitial inflammation in Alport syndrome. Human Pathology, 2010, 41, 582-593.	2.0	30
56	Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biology, 2010, 29, 346-356.	3.6	112
57	Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. Nephrology Dialysis Transplantation, 2009, 24, 1626-1630.	0.7	64
58	Treatment of Alport syndrome: beyond animal models. Kidney International, 2009, 76, 599-603.	5.2	38
59	Ccl2/Mcpâ€1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3â€deficient mice with autosomal recessive Alport nephropathy. Journal of Pathology, 2009, 218, 40-47.	4.5	35
60	Inner ear defects and hearing loss in mice lacking the collagen receptor DDR1. Laboratory Investigation, 2008, 88, 27-37.	3.7	57
61	Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrology Dialysis Transplantation, 2008, 24, 731-734.	0.7	40
62	Understanding renal disorders as systemic diseases: the fascinating world of basement membranes beyond the glomerulus. Nephrology Dialysis Transplantation, 2008, 23, 1823-1825.	0.7	2
63	Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrology Dialysis Transplantation, 2007, 22, 1062-1069.	0.7	46
64	Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney International, 2006, 70, 121-129.	5.2	243
65	Bone marrow transplantation rescues Alport mice*. Nephrology Dialysis Transplantation, 2006, 21, 2721-2723.	0.7	7
66	Chronic Renal Failure and Shortened Lifespan in COL4A3+/â^' Mice. Journal of the American Society of Nephrology: JASN, 2006, 17, 1986-1994.	6.1	39
67	Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney International, 2005, 68, 456-463.	5.2	38
68	Delayed Chemokine Receptor 1 Blockade Prolongs Survival in Collagen 4A3â€“Deficient Mice with Alport Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 977-985.	6.1	94
69	Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrology Dialysis Transplantation, 2004, 19, 1716-1723.	0.7	89
70	DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. Kidney International, 2004, 66, 102-111.	5.2	85
71	Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome11See Editorial by Abbate and Remuzzi, p. 764.. Kidney International, 2003, 63, 438-446.	5.2	196
72	X-Linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2003, 14, 2603-2610.	6.1	394

#	Article	IF	Citations
73	Novel COL4A4 splice defect and inâ€frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. Nephrology Dialysis Transplantation, 2003, 18, 1122-1127.	0.7	37
74	Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrology Dialysis Transplantation, 2002, 17, 1218-1227.	0.7	215
75	Membranous nephropathy from exposure to mercury in the fluorescentâ€tubeâ€recycling industry. Nephrology Dialysis Transplantation, 2001, 16, 2253-2255.	0.7	41
76	Sporadic case of X-chromosomal Alport syndrome in a consanguineous family. Pediatric Nephrology, 2000, 14, 758-761.	1.7	7
77	X-linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2000, 11, 649-657.	6.1	455
78	Use of psoralen-coupled nucleotide primers for screening of COL4A5 mutations in Alport syndrome. Kidney International, 1996, 50, 1363-1367.	5.2	7